Global Areds 2 Supplements Market Size, Share, And Industry Analysis Report By Product (Soft gels, Capsules, Tablets, Others), By Distribution Channel (Pharmacies, Online, Others), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Statistics, Trends and Forecast 2026-2035

Report Overview

The Global AREDS 2 Supplements Market size is expected to be worth around USD 1502.4 million by 2035 from USD 854.9 million in 2025, growing at a CAGR of 5.8% during the forecast period 2026 to 2035.

The AREDS 2 supplements market focuses on clinically validated nutritional formulas designed to slow the progression of age-related macular degeneration (AMD). These supplements combine key micronutrients, including vitamins, zinc, lutein, and zeaxanthin. Healthcare providers and patients widely recognize them as a primary preventive strategy for AMD.

AMD remains one of the leading causes of vision loss among adults aged 50 and above. Consequently, demand for evidence-based eye health supplements continues to rise globally. Consumers increasingly seek products supported by government-backed clinical research, making AREDS 2 formulations a trusted category within the broader nutraceutical market.

AREDS2 supplements reduce progression from intermediate to late AMD, with the standardized formula containing Vitamin C 500 mg, Vitamin E 400 IU, Zinc 80 mg, Copper 2 mg, Lutein 10 mg, and Zeaxanthin 2 mg. This government-confirmed efficacy gives the market strong clinical credibility.

The original AREDS2 randomized Phase III trial enrolled 4,203 participants, making it the largest government-backed clinical dataset directly supporting this supplement category. This scale of evidence strengthens physician confidence and consumer trust, driving sustained market adoption across multiple distribution channels.

Key Takeaways

• The Global AREDS 2 Supplements Market is valued at USD 854.9 million in 2025 and is projected to reach USD 1502.4 million by 2035 at a CAGR of 5.8% during the forecast period 2026 to 2035.
• The Soft gels segment holds the dominant share of 42.3% in 2025.
• The Pharmacies segment leads with a 49.1% market share in 2025.
• North America dominates the regional landscape with a 43.8% market share, valued at approximately USD 374.4 million.

By Product Analysis

Soft gels dominate with 42.3% due to superior digestibility and consumer preference among elderly users.

In 2025, Soft gels held a dominant market position in the by-product segment of the AREDS 2 Supplements Market, with a 42.3% share. Soft gels offer superior digestibility and ease of swallowing, making them highly preferred among elderly consumers. Moreover, their ability to enhance nutrient bioavailability supports strong clinical outcomes, driving continued preference among healthcare providers and patients alike.

Capsules represent a significant and growing sub-segment within the AREDS 2 supplements product landscape. Consumers value capsules for their versatility and compatibility with vegetarian and allergen-free formulations. Additionally, manufacturers increasingly adopt capsule formats to deliver combination nutrients, meeting demand for clean-label and specialized dietary supplement products.

Tablets maintain a steady presence in the market due to their established manufacturing infrastructure and cost efficiency. Tablets offer longer shelf life and precise dosage control, making them attractive for mass-market and private-label manufacturers. However, they face competition from soft gels in the premium and specialty supplement categories.

By Distribution Channel Analysis

Pharmacies dominate with 49.1% due to trusted specialist recommendations and strong consumer reliance on professional retail settings.

In 2025, Pharmacies held a dominant market position in the By Distribution Channel segment of the AREDS 2 Supplements Market, with a 49.1% share. Pharmacies benefit from direct consumer trust and professional pharmacist endorsements. Moreover, healthcare providers frequently direct AMD patients to pharmacy channels for AREDS 2 supplements, reinforcing this segment’s leadership in regulated, specialist-recommended product categories.

Online channels demonstrate rapid growth as digital retail platforms expand accessibility for AREDS 2 supplements globally. E-commerce enables consumers to compare products, access reviews, and purchase at competitive prices. Additionally, subscription-based models and auto-replenishment programs on digital platforms drive consistent repeat purchases among long-term supplement users.

Key Market Segments

By Product

• Soft gels
• Capsules
• Tablets
• Others

By Distribution Channel

• Pharmacies
• Online
• Others

Emerging Trends

Soft Gel and Advanced Delivery Formats Lead Product Innovation

Soft gel delivery formats dominate the AREDS 2 supplements market due to their superior digestibility and higher absorption rates among elderly consumers. Manufacturers actively invest in enhanced bioavailability technologies, including nano-encapsulation and lipid-based delivery systems. The annual global productivity loss from vision impairment reaches USD 411 billion, reinforcing strong commercial incentives for advanced preventive supplement innovation.

Private Label Growth and Digital Channel Expansion Reshape Market Access

Digital platforms accelerate the adoption of private label and generic AREDS 2 options, driven by rising price sensitivity among consumers. Online marketplaces enable smaller brands to reach broader audiences without traditional retail infrastructure. Moreover, specialist-driven pharmacy channels continue to strengthen their position as trusted recommendation points, creating a dual-channel growth dynamic across premium and value product tiers.

Drivers

Aging Population and Rising AMD Prevalence Fuel Supplement Demand

The escalating global aging population directly amplifies the incidence of age-related macular degeneration, expanding the core consumer base for AREDS 2 supplements. The NIH NEI, a 2024 update, confirmed that AREDS2 supplements slowed progression even in late-stage dry AMD, extending commercial relevance beyond intermediate-stage use cases and strengthening long-term market demand.

Clinical Evidence and Consumer Awareness Strengthen Market Adoption

Rising consumer awareness of eye health, supported by government-backed awareness campaigns and published clinical evidence, actively drives AREDS 2 supplement adoption. According to the WHO, 50% of people globally who need cataract surgery lack access, reinforcing broad unmet ophthalmic care demand. This gap encourages preventive supplement adoption as an accessible and affordable alternative among at-risk populations.

Restraints

Regulatory Compliance Costs Create Barriers for New Market Entrants

Stringent regulatory compliance requirements significantly elevate production costs and create high market entry barriers for emerging manufacturers. Regulatory agencies in key markets demand rigorous safety, efficacy, and labeling standards for eye health supplements. 1 billion cases of preventable or untreated vision impairment exist globally, yet complex compliance frameworks limit the speed at which new preventive products reach underserved markets.

General Eye Health Substitutes Compete on Price and Availability

The availability of competing general eye health supplements and multivitamins as cost-effective substitutes restrains premium AREDS 2 market growth. Many consumers and budget-conscious buyers perceive broader multivitamin products as sufficient alternatives. Consequently, AREDS 2 manufacturers face pressure to differentiate on clinical validation, ingredient specificity, and specialist endorsement to retain market share against lower-cost options.

Growth Factors

Asia Pacific Expansion and Hybrid Formulations Unlock New Revenue Streams

Asia Pacific markets present significant untapped growth potential for AREDS 2 supplement manufacturers. Affordable local innovations and contract manufacturing enable market entry at competitive price points. At least 2.2 billion people globally experience vision impairment, representing an enormous epidemiological demand pool. Moreover, hybrid formulations combining AREDS 2 nutrients with additional benefits like CoQ10 for heart health attract broader consumer segments.

E-Commerce Growth and Professional Integration Accelerate Market Reach

Rapid growth of online e-commerce channels enhances accessibility and consumer choice for AREDS 2 supplements globally. Digital retail reduces geographic and economic access barriers for underserved markets. Additionally, increased integration of AREDS 2 supplements into professional eye care plans through specialist recommendations and long-term clinical studies strengthens product credibility. These professional endorsements support sustained adoption among newly diagnosed and at-risk AMD patients.

Regional Analysis

North America Dominates the AREDS 2 Supplements Market with a Market Share of 43.8%, Valued at USD 374.4 Million

North America leads the global AREDS 2 supplements market, holding a dominant 43.8% share valued at USD 374.4 million in 2025. The region benefits from strong clinical awareness, government-backed research from NIH and NEI, and a large aging population with high AMD prevalence. Moreover, well-established pharmacy networks and robust e-commerce infrastructure support consistent consumer access to clinically validated formulations.

Europe represents a mature and steadily growing market for AREDS 2 supplements, supported by an aging demographic and rising ophthalmic healthcare awareness. Regulatory frameworks across the EU promote evidence-based supplement standards, encouraging consumer confidence. Additionally, specialist-driven pharmacy and optical retail channels actively support product adoption among middle-aged and elderly populations seeking preventive eye health solutions.

Asia Pacific emerges as the fastest-growing regional market for AREDS 2 supplements, driven by a rapidly aging population and increasing disposable incomes. Countries including China, Japan, and India present large addressable patient pools for AMD-related supplementation. Furthermore, expanding e-commerce platforms and growing health awareness among urban consumers accelerate regional adoption of clinically supported eye health products.

The Middle East and Africa market for AREDS 2 supplements remains in an early growth stage, constrained by limited specialist eye care infrastructure and lower consumer awareness. However, increasing urbanization and rising healthcare investment across GCC nations create new opportunities. Consequently, premium supplement brands targeting ophthalmology clinics and private healthcare networks gain traction in this developing regional market.

Key Regions and Countries

North America

• US
• Canada

Europe

• Germany
• France
• The UK
• Spain
• Italy
• Rest of Europe

Asia Pacific

• China
• Japan
• South Korea
• India
• Australia
• Rest of APAC

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC
• South Africa
• Rest of MEA

Key Players Analysis

Bausch + Lomb holds a well-established position in the global AREDS 2 supplements market, leveraging decades of ophthalmic expertise and a trusted brand reputation. The company distributes its eye health supplement portfolio through pharmacy networks, optical retailers, and healthcare professional channels. Moreover, its integration across both pharmaceutical and consumer health divisions enables a comprehensive approach to AMD supplement marketing and clinical positioning.

Alcon Inc. actively strengthens its presence in the preventive eye health category through its broad ophthalmic product ecosystem. The company benefits from deep relationships with ophthalmologists and specialist eye care practitioners globally. Additionally, Alcon’s established surgical and vision care portfolio creates strong cross-referral opportunities, positioning its AREDS 2 supplement offerings as a natural extension of its clinical eye care solutions for AMD patients.

Nature Made (Pharmavite LLC) brings broad consumer market reach and strong retail pharmacy partnerships to the AREDS 2 supplements segment. The brand enjoys high consumer recognition built on decades of nutritional supplement credibility. Furthermore, Nature Made actively leverages its pharmacist recommendation equity and third-party quality certifications to differentiate its eye health formulations in a competitive and clinically sensitive market environment.

EyePromise (ZeaVision, LLC) focuses specifically on eye health nutrition, making it a highly specialized competitor in the AREDS 2 supplements landscape. The company emphasizes scientific research and zeaxanthin-rich formulations, targeting both clinical and direct-to-consumer channels. Consequently, EyePromise builds strong credibility among optometrists and retinal specialists who recommend evidence-based nutritional support as part of structured AMD management protocols.

Top Key Players in the Market

• Bausch + Lomb
• Alcon Inc.
• Nature Made (Pharmavite LLC)
• EyePromise (ZeaVision, LLC)
• MacuHealth
• Viteyes (Vitamin Health, Inc.)
• Codeage LLC
• NATURELO Premium Supplements, LLC
• NutraChamps Inc.
• VISTA
• Pure Encapsulations
• Nordic Naturals

Recent Developments

• In 2025, Bausch + Lomb had the most notable recent activity in the AREDS 2 sector among the listed companies. The company continues to market and sell its flagship PreserVision AREDS 2 Formula eye vitamins. In its official 3Q 2025 earnings presentation, Bausch + Lomb reported growth in its eye vitamins franchise, with the consumer vitamins segment contributing to overall Vision Care revenue increases.
• In 2025, MacuHealth continues to market its core triple-carotenoid formulas, which are explicitly based on the AREDS 2 study but include 10 mg of meso-zeaxanthin in addition to lutein and zeaxanthin. The company website emphasizes this as an improvement for macular pigment and AMD support.

Report Scope